| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 26.04.
| Pharming Group N.V.: Pharming reports financial results first quarter 2012 | | 57 | Thomson Reuters ONE |
| Leiden, The Netherlands, April 26, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the first quarter ended March...
Mehr lesen zu:
Pharming Group N.V.: Pharming reports financial results first quarter 2012 | |
| 04.04.
| Exclusive Video Q&A With Sijmen de Vries, CEO of Pharming | | 39 | MarketWire |
| LOS ANGELES, CA -- (Marketwire) -- 04/04/12 -- Trading on the Euronext, Pharming Group NV (EURONEXT: PHARM) produces, purifies and formulates recombinant human proteins using its transgenic technology...
Mehr lesen zu:
Exclusive Video Q&A With Sijmen de Vries, CEO of Pharming | |
| 26.03.
| Pharming Group N.V.: Pharming and Hyupjin Corporation announce commercialisation agreement for RUCONEST in Korea | | 61 | Thomson Reuters ONE |
| Leiden, The Netherlands, March 26, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that it has entered into an agreement with Hyupjin Corporation...
Mehr lesen zu:
Pharming Group N.V.: Pharming and Hyupjin Corporation announce commercialisation agreement for RUCONEST in Korea | |
| 26.03.
| Pharming Group N.V.: Pharming and Hyupjin Corporation announce comme... | | 1 | InvestEgate |
| 01.03.
| Pharming Group N.V.: Pharming announces preliminary financial results 2011 | | 49 | Thomson Reuters ONE |
| Leiden, The Netherlands, March 1, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its preliminary (unaudited) financial results for the...
Mehr lesen zu:
Pharming Group N.V.: Pharming announces preliminary financial results 2011 | |
| 01.03.
| Pharming Group N.V.: Pharming announces preliminary financial result... | | - | InvestEgate |
| 14.02.
| Pharming Group N.V.: Pharming and Transmedic announce distribution agreement for RUCONEST | | 48 | Thomson Reuters ONE |
| Leiden, The Netherlands, February 14, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that it has entered into an agreement with Transmedic...
Mehr lesen zu:
Pharming Group N.V.: Pharming and Transmedic announce distribution agreement for RUCONEST | |
| 14.02.
| Pharming Group N.V.: Pharming and Transmedic announce distribution a... | | 2 | InvestEgate |
| 06.01.
| Pharming Group N.V.: Pharming redeems part of convertible bond | | 73 | Thomson Reuters ONE |
| Leiden, The Netherlands, 06 January, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has redeemed part of its €8.4 million convertible...
Mehr lesen zu:
Pharming Group N.V.: Pharming redeems part of convertible bond | |
| 16.12.
| Pharming Group N.V.: Pharming announces agreement with Renova Life targeting factor VIII for the treatment of haemophilia A | | 11 | Thomson Reuters ONE |
| Leiden, The Netherlands, December 16, 2011. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has signed a service agreement with Renova...
Mehr lesen zu:
Pharming Group N.V.: Pharming announces agreement with Renova Life targeting factor VIII for the treatment of haemophilia A | |
| 12.12.
| Pharming Group N.V.: Pharming granted U.S. patent on C1 inhibitor use in ischemia reperfusion injury indications | | 57 | Thomson Reuters ONE |
| Leiden, The Netherlands, December 12, 2011. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announces that the United States Patent and Trademark Office (USPTO)...
Mehr lesen zu:
Pharming Group N.V.: Pharming granted U.S. patent on C1 inhibitor use in ischemia reperfusion injury indications | |
| 07.12.
| Pharming Group N.V.: Santarus and Pharming announce oral presentations of retrospective analyses of data from RHUCIN clinical program at World Allergy Congress | | 52 | Thomson Reuters ONE |
| Leiden, The Netherlands, December 7, 2011. Â Biotech company Pharming Group NV (http://www.pharming.com/) (NYSE Euronext: PHARM) and specialty biopharmaceutical company Santarus, Inc. (http://www.santarus.com/)...
Mehr lesen zu:
Pharming Group N.V.: Santarus and Pharming announce oral presentations of retrospective analyses of data from RHUCIN clinical program at World Allergy Congress | |
| 07.12.
| Santarus and Pharming Announce Oral Presentations of Retrospective Analyses of Data from RHUCIN Clinical Program at World Allergy Congress | | 31 | Business Wire |
| Santarus,
Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM)
today announced that retrospective analyses of integrated efficacy data
and immuno-safety...
Mehr lesen zu:
Santarus and Pharming Announce Oral Presentations of Retrospective Analyses of Data from RHUCIN Clinical Program at World Allergy Congress | |
